Acute Sympotomatic Seizure Secondary to Autoimmune Encephalitis and Autoimmune-associated Epilepsy
Launched by LIU YONGHONG · Jun 13, 2022
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Confirmed autoimmune encephalitis (2016,Lancet);
- • 2. Meet the classification criteria for epilepsy (2017,International League Against Epilepsy);
- • 3. Patients who still have seizures after taking ASM after the control of AE disease were included in the third part of the study;
- • 4. All patients volunteered and signed an informed consent form;
- Exclusion Criteria:
- • 1. Incomplete key clinical data;
- • 2. People with epilepsy or other intracranial diseases before diagnosis;
- • 3. There is no epileptic author during the onset of autoimmune encephalitis;
About Liu Yonghong
Liu Yonghong is a dedicated clinical trial sponsor committed to advancing healthcare through innovative research and development. With a focus on enhancing therapeutic options and improving patient outcomes, Liu Yonghong collaborates with leading institutions and experts to conduct rigorous clinical trials across various therapeutic areas. The sponsor emphasizes adherence to ethical standards and regulatory compliance, ensuring the safety and well-being of participants while generating valuable data to inform future medical practices. Through a commitment to scientific excellence and collaboration, Liu Yonghong aims to contribute significantly to the enhancement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xi'an, Shaanxi, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials